AKT1 and gastric cancer: A potential new biomarker and therapeutic target for GC is the oncogenic lncRNA WFDC21P, which accelerates tumor growth through the WFDC21P/Ran/Akt/GSK3/ β-catenin axis and is favorably controlled by transcription factor FOXP3 [27].